<DOC>
	<DOCNO>NCT00496626</DOCNO>
	<brief_summary>This China registration study . A randomized , double-blind , placebo-controlled immunogenicity safety study Chinese female participant age 9 45 year male participant age 9 15 year . Approximately 600 participant randomize 1:1 ratio receive either vaccine aluminum-containing placebo . Each participant receive one injection visit Day 1 , Month 2 , Month 6 . Vaccine placebo give 0.5-mL intramuscular injection . Serum collect participant evaluate immune response anti-Human Papillomavirus ( HPV ) 6/11/16/18 Luminex Assay . At Month 2 , Month 6 , Month 7 , subject evaluate new medical condition health concern Serious Adverse Experiences throughout study . The primary objective evaluate vaccine-induced serum anti-HPV 6 , 11 , 16 18 antibody titer follow 3-dose regimen Gardasil® compare placebo .</brief_summary>
	<brief_title>An Immunogenicity Safety Study Gardasil® Chinese Subjects ( V501-030 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female participant age 945 year old male participant age 915 year old Participants agree provide study personnel primary telephone number well alternate telephone number followup purpose Not pregnant ( demonstrated negative urine betaHuman Chorionic Gonadotropin ( betaHCG ) test ) postpubertal female participant</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HPV infection</keyword>
</DOC>